[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Puretech Health Plc ADR (PRTC)

Puretech Health Plc ADR (PRTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 420,143
  • Shares Outstanding, K 24,342
  • Annual Sales, $ 4,660 K
  • Annual Income, $ -109,740 K
  • EBIT $ 0 M
  • EBITDA $ -95 M
  • 60-Month Beta 1.15
  • Price/Sales 91.17
  • Price/Cash Flow N/A
  • Price/Book 1.38

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.58 +5.61%
on 05/05/26
19.33 -9.42%
on 05/01/26
-0.30 (-1.66%)
since 04/13/26
3-Month
14.50 +20.76%
on 03/30/26
19.33 -9.42%
on 05/01/26
+0.05 (+0.29%)
since 02/10/26
52-Week
14.50 +20.76%
on 03/30/26
19.92 -12.10%
on 01/16/26
+0.51 (+3.00%)
since 05/13/25

Most Recent Stories

More News
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

Presentations to highlight differentiated approach to advancing deupirfenidone, reinforcing its potential to serve as a new standard of care within the evolving idiopathic pulmonary fibrosis treatment...

PRTC.LN : 131.400 (+1.70%)
PRTC : 17.51 (+1.45%)
PureTech Announces Annual Results for Year Ended December 31, 2025

Refined strategy and disciplined execution position Company to unlock value from its portfolio, which includes Celea Therapeutics’ Phase 3-ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop...

PRTC.LN : 131.400 (+1.70%)
PRTC : 17.51 (+1.45%)
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

PureTech to maintain its primary listing on the London Stock Exchange Simplification of listing structure expected to enhance operational efficiency and focus resources...

PRTC.LN : 131.400 (+1.70%)
PRTC : 17.51 (+1.45%)
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value,...

PRTC.LN : 131.400 (+1.70%)
PRTC : 17.51 (+1.45%)
BNTC : 11.65 (-1.60%)
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)

Phase 1b dataset with LYT-200 demonstrates complete responses and favorable tolerability across both R/R HR-MDS and R/R AML PureTech’s Founded Entity, Gallop Oncology,...

PRTC.LN : 131.400 (+1.70%)
PRTC : 17.51 (+1.45%)
PureTech Health: Notice of Results

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2025, on Wednesday,...

PRTC.LN : 131.400 (+1.70%)
PRTC : 17.51 (+1.45%)
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

Deupirfenidone 825 mg TID monotherapy significantly slowed lung function decline versus placebo at 26 weeks in people with idiopathic pulmonary fibrosis (adjusted mean FVC difference 91 mL; p=0.02), approaching...

PRTC.LN : 131.400 (+1.70%)
PRTC : 17.51 (+1.45%)
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into...

PRTC.LN : 131.400 (+1.70%)
PRTC : 17.51 (+1.45%)
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value,...

PRTC.LN : 131.400 (+1.70%)
PRTC : 17.51 (+1.45%)
PureTech to Present at the Leerink Partners Global Healthcare Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value,...

PRTC.LN : 131.400 (+1.70%)
PRTC : 17.51 (+1.45%)

Business Summary

PureTech Health plc is a clinical-stage biotherapeutics company. It engages in discovering, developing and commercializing medicines for devastating diseases, including inflammatory and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological...

See More

Key Turning Points

3rd Resistance Point 18.41
2nd Resistance Point 18.08
1st Resistance Point 17.80
Last Price 17.51
1st Support Level 17.19
2nd Support Level 16.86
3rd Support Level 16.58

See More

52-Week High 19.92
Fibonacci 61.8% 17.85
Last Price 17.51
Fibonacci 50% 17.21
Fibonacci 38.2% 16.57
52-Week Low 14.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.